Weight-loss drugs have moved from niche medical treatments to mainstream consumer products. Television commercials, celebrity endorsements, and telehealth platforms have helped propel GLP-1–based therapies into the public consciousness — and into millions of medicine cabinets.
But as demand has surged, so have tensions across the healthcare, regulatory, and investment landscape.
That tension came sharply into focus today after Hims & Hers Health, Inc. (HIMS) shares fell more than 20% following news that Novo Nordisk has filed a lawsuit seeking to permanently block Hims from selling compounded versions of drugs that allegedly infringe on Novo’s patents — including versions tied to Wegovy, its blockbuster obesity treatment.
The dispute highlights a broader reckoning underway in the fast-growing — and fast-changing — obesity drug market.
A Market Built on Demand — and a Regulatory Loophole
GLP-1 drugs such as Wegovy (Novo Nordisk) and Zepbound/Mounjaro (Eli Lilly) have reshaped expectations around medical weight loss. Unprecedented demand led analysts to project a global obesity drug market of $150 billion to $200 billion by the early 2030s.
But demand quickly ran into supply constraints, high prices, and limited insurance coverage. That gap created an opening for compounded versions of GLP-1 drugs — products mixed by pharmacies and prescribed on a case-by-case basis under the Federal Food, Drug, and Cosmetic Act.
Under U.S. law, compounding is permitted in limited circumstances, such as:
- When a patient cannot tolerate an ingredient in a branded drug
- When a specific dosage or formulation is medically necessary
- When an FDA-approved drug is in short supply
Novo has estimated that as many as 1.5 million Americans are currently using compounded GLP-1 drugs.
Telehealth companies like Hims moved aggressively into this space, marketing lower-cost alternatives to branded therapies — often directly to cash-pay consumers.
Novo vs. Hims: From Tension to Litigation
Novo Nordisk’s lawsuit represents a major escalation.
The company is asking the court to:
- Permanently ban Hims from selling compounded versions of its drugs
- Recover damages for alleged patent infringement
Novo argues that Hims’ compounded products contain semaglutide, the active ingredient in Wegovy, which is protected by U.S. patents through 2032. Importantly, Novo has stated that semaglutide is no longer in short supply in the U.S. — undermining one of the key legal justifications for compounding.
Hims, for its part, has argued that its products are legal because they are “personalized” in dosage. The company had planned to offer an oral obesity pill for as little as $49 for the first month, roughly $100 less than Novo’s approved Wegovy pill.
However, the pressure intensified last week when:
- Hims said it would stop offering its newly launched obesity pill copycat
- The FDA announced it planned to take legal action against Hims
- Federal regulators said they would restrict access to GLP-1 ingredients used in non-approved compounded drugs
- The FDA indicated it may refer the matter to the Department of Justice over potential violations of federal law
In a public statement, Hims called Novo’s lawsuit “a blatant attack by a Danish company on millions of Americans who rely on compounded medications for access to personalized care,” accusing Big Pharma of weaponizing the U.S. judicial system to limit consumer choice.
FDA Scrutiny Raises the Stakes
The FDA has made clear it is increasingly concerned about the quality, safety, and legality of compounded GLP-1 products.
Unlike branded drugs:
- Compounded drugs are not FDA-approved
- They have not undergone clinical trials to demonstrate efficacy
- Oversight is more fragmented
According to legal experts, potential FDA enforcement actions could include:
- Warning letters
- Court injunctions (with DOJ involvement)
- Administrative seizure of products
Novo and Eli Lilly have both taken aggressive steps over the past two years to crack down on compounding pharmacies and marketers. Novo has reportedly filed around 130 lawsuits related to deceptive marketing practices and consumer fraud, while Lilly has pursued similar actions tied to tirzepatide, its active ingredient.
Investors Reassess the Obesity Drug Opportunity
Beyond the immediate legal headlines, the episode underscores a broader shift in how Wall Street views the obesity drug market.
While demand remains strong, expectations around pricing power and long-term market size are being recalibrated:
- Forecasts for the global obesity market have fallen roughly 30%, to around $100 billion by 2030
- The once-common $150 billion target has been pushed out to 2035 by some analysts
- Jefferies recently cut its peak market estimate by 20%, projecting a peak of $80 billion
As Jefferies analyst Michael Leuchten put it: “That $150 billion pie is gone, even if you’re very bullish on volumes.”
Competition is intensifying as well. Novo and Lilly remain the dominant players, but falling U.S. prices, the expected entry of new drugs, and eventual generic competition are reshaping the outlook — particularly in the cash-pay consumer segment.
What This Means Going Forward
For consumers, the crackdown on compounding could limit access to lower-cost alternatives — at least in the near term.
For telehealth companies, the legal and regulatory risks around drug development and distribution are becoming harder to ignore.
And for investors, the GLP-1 market is entering a new phase: one where growth remains substantial, but margins, market share, and timelines are far less certain than they appeared just a year ago.
The obesity drug boom is real. But as the fight between Novo Nordisk, Hims, the FDA, and regulators shows, the path forward will be shaped as much by courts and policymakers as by science and demand.
